Meeting Challenges in the Diagnosis and Treatment of Glaucoma

Dear Colleagues,

Glaucoma is the second leading cause of irreversible blindness worldwide, affecting nearly eighty million people globally, and is expected to keep pace with the rapidly expanding world population. It is a multifactorial progressive optic neurodegenerative disorder that leads to the loss of optic nerve head tissue and thinning of the retinal nerve fiber layer, resulting in corresponding visual field defects with or without elevated intraocular pressure (IOP). The systemic risk factors include age over 55 years, black or Hispanic/Latino lineage, a family history of glaucoma, diabetes, and hypertension. The physical ocular risk factors are elevated IOP, thin central corneal thickness, large cup-to-disc ratio, disc hemorrhage, and low ocular perfusion pressure.

Many glaucoma studies have documented factors that result in blindness, such as late detection of the disease, poor control/wide fluctuations of IOP and non-compliance with therapy. In addition, the current methods used for diagnosing glaucoma, IOP measurement, visual field testing and optic nerve evaluation all suffer from being subjective in nature.

The aim of this Special Issue is to focus on the remarkable advances in the fields of glaucoma diagnosis, retinal imaging, targeted medical/laser therapy, micro invasive glaucoma surgeries (MIGs), wound healing, compliance, and understanding comorbidities. We invite investigators to submit both their original research and reviews on the following topics relating to glaucoma: biomechanics, advanced imaging technologies, targeted medical therapy, traditional and microinvasive glaucoma surgeries (MIGS), reducing noncompliance, and role of co-morbidities.

Dr. Karanjit S. Kooner
Dr. Osamah J. Saeedi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.